BUSINESS UPDATE: Approval and Licence in place for commercial sale of GMP pharmaceutical cannabis
Great day for Celadon Pharmaceuticals as UK regulators update its cultivation and production licence, enabling the company to commercially supply its cannabis product to the pharmaceutical market. This follows Celadon’s landmark GMP registration in January 2023, understood to be the first such registration for high-THC cannabis since the legalisation of medical cannabis in 2018.
OTHER POSTS
-
PRESS: Britain could be getting high on the benefits of a full-scale medical cannabis industry
-
PRESS: British Pain Society features Celadon Pharmaceuticals Plc
-
PRESS: Celadon Pharmaceutical’s CEO Jim Short featured discussing new MHRA framework
-
PRESS: Inside huge top-secret legal cannabis facility hidden away in Birmingham that is the size of three football pitches